Dynavax Announces HEPLISAVTM Data to Be Presented at IDSA Medical Conference
September 22 2009 - 6:45AM
Business Wire
Dynavax Technologies Corporation (Nasdaq:DVAX) today announced
that an abstract with chronic kidney disease patient data for
HEPLISAVTM, an investigational adult hepatitis B vaccine, will be
presented at the 47th Annual Meeting of the Infectious Disease
Society of America (IDSA) in Philadelphia, Pennsylvania, from
October 29 through November 1, 2009.
For more information on this conference, please visit the IDSA
website at http://www.idsociety.org.
About HEPLISAV
HEPLISAV is a Phase 3 investigational adult hepatitis B vaccine
designed to provide increased, rapid protection with fewer doses
than current licensed vaccines. Over 2,500 individuals have been
vaccinated with HEPLISAV to date. Dynavax is developing HEPLISAV
for populations that are less responsive to current licensed
vaccines, including adults over 40 years of age, individuals with
chronic kidney disease, and others.
Dynavax has worldwide commercial rights to HEPLISAV, which
combines hepatitis B surface antigen (HBsAg) with a proprietary
Toll-like Receptor 9 agonist to enhance the immune response.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage
biopharmaceutical company, discovers and develops novel products to
prevent and treat infectious diseases. The Company’s lead product
candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B
vaccine designed to provide more rapid and increased protection
with fewer doses than current licensed vaccines. For more
information visit www.dynavax.com.
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From May 2024 to Jun 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Jun 2023 to Jun 2024